U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Drug Databases
  3. Drug Shortages

FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Report a Drug Shortage | FAQ | Background Info | Get Email Alerts | Download Current Drug Shortages | Contact Us

Start Over | Back to Previous Screen

Remifentanil Hydrochloride Injection
Status: Currently in Shortage
»Date first posted: 06/28/2022
»Therapeutic Categories: Analgesia/Addiction

Expand all

Fresenius Kabi USA, LLC (Revised 04/01/2025)

Company Contact Information:
888-386-1300

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03) Unavailable Backordered. Next release March 2025. Check wholesalers for inventory. Demand increase for the drug
Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05) Available Check wholesalers for inventory
Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10) Unavailable Backordered. Next release April 2025; Check wholesalers for inventory. Demand increase for the drug

Hikma Pharmaceuticals USA, Inc. (Reverified 02/14/2025)

Company Contact Information:
800-631-2174

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10) Unavailable Additional lots will be available in the February 2025 timeframe. Product will be made available as it is released. Demand increase for the drug
Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10) Unavailable Additional lots will be available in the February 2025 timeframe. Product will be made available as it is released. Demand increase for the drug
Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10) Unavailable Additional lots will be available in the February 2025 timeframe. Product will be made available as it is released. Demand increase for the drug

Mylan Institutional, a Viatris Company (Reverified 03/20/2025)

Company Contact Information:
800-796-9526

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Ultiva, Injection, 2 mg (NDC 72078-035-02) Available
Ultiva, Injection, 5 mg (NDC 67457-198-10) Unavailable Next supply in March 2025 Demand increase for the drug
Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01) Available
Back to Top